Slb Limited/Nv
—- Market cap
- —
- Debt
- —
- Cash
- −$3.04B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $7.68B · View financials
Decision snapshot: SLB stock price at discount vs NOV $57.10 current versus $128.89 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at NOV's multiple
Implied fair value · at SLB's multiple
Snapshot Sep 8, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Lower P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Ten period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
SLB LIMITED/NV · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
NOV INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe SLB can sustain its superior margin structure and return on capital while closing the gap to NOV-implied valuation, then SLB is worth accumulating because its operating quality is far stronger than NOV's and the relative upside is large; however, the case is less compelling if you require a strong near-term catalyst because the Piotroski score is only 4/9 and the DCF range is below the current price.
SLB's current price of $49.59 is well below NOV-implied price of $117.08, suggesting significant upside on a relative valuation basis. The market is likely discounting SLB less harshly than NOV because SLB already shows much stronger margins, returns, and profitability.
Supporting Metrics